WithdrawnPhase 1NCT03205891

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Studying Anaplastic large cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Michelle A. Fanale, MD
M.D. Anderson Cancer Center
Intervention
Brentuximab Vedotin(drug)
Eligibility
18 years · All sexes
Timeline
2018 – 2021

Collaborators

Takeda

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03205891 on ClinicalTrials.gov

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic large cell lymphoma →

← Back to all trials